BioCentury
ARTICLE | Product Development

Sanitizing PPAR

August 6, 2007 7:00 AM UTC

Rheoscience A/S believes its partial agonist of peroxisome proliferation activated receptor gamma will have a better safety profile than the full PPAR agonists that are marketed to help diabetic patients control their blood sugar. The company began Phase III testing of balaglitazone last week.

Marketed insulin sensitizers Avandia rosiglitazone and Actos pioglitazone, both members of a chemical class known as thiazolidinediones, are now the focus of the hot debate over whether one of the TZDs imposes an excessive risk of cardiac complications in diabetics. Avandia is marketed by GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.), while Actos is marketed by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) and Eli Lilly and Co. (LLY, Indianapolis, Ind.)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article